Table 4.

Manufacturer's Labeling: Weight-Based Precautions for Hormonal Contraception

Triphasic oral contraceptive (eg, Ortho Tri Cyclen, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ)Increased body weight and surface area are associated with decreased hormone concentration (overweight is not listed as a precaution).
Monophasic Oral Contraceptive (eg, Loestrin 24 Fe, Warner Chilcott, Rockaway, NJ)No weight-specific comments.
Progesterone-only contraceptive (eg, Ortho Micronor, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ)No weight-specific comments.
Transdermal contraceptive (eg, Ortho Evra, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ)Consider decreased effectiveness >90 kg (this is listed as a precaution).
Intravaginal ring (eg, Nuva ring, Schering-Plough Corp., Kenilworth, NJ)No weight-specific comments.
Implantable progesterone (eg, Implanon, Schering-Plough Corp., Kenilworth, NJ)Effectiveness not defined because women with >130% of ideal body weight were not studied. However, the hormonal concentration is inversely related to body weight and thus may be less effective in overweight patients.
Injectable progesterone (eg, Depo-provera, Pfizer, Inc., New York, NY)No weight-specific comments.
Hormonal intrauterine device (eg, Mirena, Bayer HealthCare Pharmaceuticals, Montville, NJ)No weight-specific comments.